Kyverna Therapeutics, Inc. Common Stock (KYTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $319.27M
Last updated: Nov 17, 2026 at 11:06 AM ET
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financials: Revenue, Profit and Cash Flow
Kyverna Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$161.31M, operating cash flow was -$153.71M and free cash flow was -$154.84M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$41.94M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $169.83M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $7.03M | +24.2% | 100.0% | -418.3% | -411.3% |
| Dec 2021 | $5.66M | N/A | 100.0% | -465.8% | -465.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.03M | $5.66M |
| Cost of revenue | $0 | $0 | $0 | $1.05M | $586.00K |
| Gross profit | $0 | $0 | $0 | $7.03M | $5.66M |
| Research and development | $133.72M | $112.47M | $49.92M | $28.40M | $25.85M |
| Operating income | -$169.83M | -$142.60M | -$62.41M | -$29.38M | -$26.35M |
| Net income | -$161.31M | -$127.48M | -$60.37M | -$28.89M | -$26.35M |
| EBITDA | N/A | N/A | -$61.87M | -$27.78M | -$25.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.02M | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | -$368.00K | $0 | $0 | $0 | -$563.00K | $0 | $0 | $0 | -$17.16M |
| Operating income | -$42.90M | -$39.56M | -$41.37M | -$39.28M | -$38.73M | -$44.41M | -$47.41M | -$41.04M | -$38.77M | -$33.44M | -$29.36M | -$21.38M |
| Net income | -$41.94M | -$38.32M | -$39.73M | -$37.80M | -$36.79M | -$42.08M | -$44.63M | -$37.49M | -$34.49M | -$28.80M | -$26.69M | -$20.67M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $28.71M by $95.38M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total assets | $293.83M | $304.64M | $75.19M | $66.92M | $85.49M |
| Current assets | $282.95M | $290.60M | $60.66M | $53.25M | $77.09M |
| Cash and equivalents | $124.09M | $96.62M | $34.65M | $37.73M | $76.07M |
| Total liabilities | $61.55M | $38.06M | $26.02M | $20.25M | $131.74M |
| Short-term debt | $3.97M | $3.94M | $2.92M | $2.28M | $814.00K |
| Long-term debt | $24.74M | $0 | N/A | N/A | N/A |
| Shareholder equity | $232.28M | $266.59M | -$131.40M | $46.68M | -$46.25M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $189.44M | $219.82M | $257.02M | $293.83M | $187.16M | $226.51M | $260.65M | $304.64M | $339.20M | $363.12M | $389.98M | $75.19M |
| Total liabilities | $56.28M | $54.27M | $61.44M | $61.55M | $35.21M | $42.13M | $36.65M | $38.06M | $36.49M | $29.61M | $28.99M | $26.02M |
| Cash and equivalents | $31.82M | $31.81M | $32.19M | $124.09M | $34.16M | $53.44M | $56.87M | $96.62M | $104.66M | $131.62M | $224.29M | $34.65M |
| Shareholder equity | $133.15M | $165.55M | $195.58M | $232.28M | $151.95M | $184.38M | $224.01M | $266.59M | $302.71M | $333.51M | $360.99M | $49.18M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$153.71M | -$114.25M | -$52.41M | -$36.11M | -$22.16M |
| Capital expenditures | $1.13M | $2.21M | $621.00K | $768.00K | $1.29M |
| Free cash flow | -$154.84M | -$116.45M | -$53.03M | -$36.88M | -$23.44M |
| Share repurchases | $475.00K | $3.36M | $1.65M | N/A | N/A |
| Investing cash flow | $40.02M | -$160.90M | -$8.79M | -$14.10M | -$1.29M |
| Financing cash flow | $141.17M | $337.11M | $58.12M | $11.88M | $72.52M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.37M | -$40.31M | -$41.60M | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.06M | -$27.49M | -$24.18M | -$25.52M | -$18.56M |
| Capital expenditures | $525.00K | $548.00K | $0 | $537.00K | $392.00K | $204.00K | $0 | $532.00K | $102.00K | $1.03M | $543.00K | $334.00K |
| Free cash flow | -$35.89M | -$40.85M | -$41.60M | -$34.06M | -$43.71M | -$32.15M | -$44.91M | -$37.59M | -$27.59M | -$25.20M | -$26.07M | -$18.90M |
Frequently Asked Questions About KYTX
What is Kyverna Therapeutics, Inc. Common Stock's annual revenue?
Kyverna Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Kyverna Therapeutics, Inc. Common Stock profitable?
No. Kyverna Therapeutics, Inc. Common Stock reported net income of -$161.31M for the fiscal year ended Dec 31, 2025.
How much free cash flow does KYTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$153.71M minus capital expenditures of $1.13M produced free cash flow of -$154.84M.
How much debt does Kyverna Therapeutics, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $24.74M, short-term debt of $3.97M and cash and equivalents of $124.09M.
KYTX pages: Overview, Earnings, Forecast, Financials, Competitors